Article

OSI collaborates on drug's sustained release

Fort Collins, CO?PR Pharmaceuticals (PRP) will work with OSI Pharmaceuticals to develop a sustained-release formulation of pegaptanib sodium injection (Macugen) using its proprietary ProPhase encapsulation technology.

Fort Collins, CO-PR Pharmaceuticals (PRP) will work with OSI Pharmaceuticals to develop a sustained-release formulation of pegaptanib sodium injection (Macugen) using its proprietary ProPhase encapsulation technology.

The deal gives OSI an exclusive license to use the encapsulation technology with the drug in the treatment of eye diseases. PRP will develop the formulations and manufacture the test product for non-clinical and clinical trials.

OSI's eye disease unit, Eyetech Pharmaceuticals, will be responsible for clinical development activities and may manufacture and commercialize any resulting product.

Pegaptanib sodium injection was approved Feb. 2 for sale in the Europe-and previously was marketed in the United States, Canada, and five other countries-for the treatment of neovascular age-related macular degeneration. Pfizer Inc. has exclusive rights to market the drug outside the United States under a royalty-bearing license agreement.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.